•
Mar 31, 2023

ICU Medical Q1 2023 Earnings Report

ICU Medical's first quarter results were generally in line with expectations, with revenue increasing compared to the same period last year and adjusted diluted earnings per share decreasing.

Key Takeaways

ICU Medical reported first quarter 2023 revenue of $568.6 million, a gross profit of $192.0 million, and a net loss of $(9.8) million, or $(0.41) per diluted share. Adjusted diluted earnings per share was $1.74, and adjusted EBITDA was $102.0 million.

First quarter revenue was $568.6 million, compared to $543.1 million in the same period last year.

GAAP gross profit for the first quarter was $192.0 million, compared to $168.8 million in the same period last year.

GAAP net loss was $(9.8) million, or $(0.41) per diluted share, compared to $(38.1) million, or $(1.61) per diluted share, for the same period last year.

Adjusted diluted earnings per share was $1.74, compared to $1.82 for the first quarter of 2022.

Total Revenue
$569M
Previous year: $543M
+4.7%
EPS
$1.74
Previous year: $1.82
-4.4%
Adjusted EBITDA
$102M
Previous year: $84.9M
+20.1%
Gross Margin
34%
Previous year: 31%
+9.7%
Gross Profit
$192M
Previous year: $169M
+13.8%
Cash and Equivalents
$221M
Previous year: $329M
-32.9%
Free Cash Flow
$27.1M
Previous year: -$24.9M
-208.6%
Total Assets
$4.47B
Previous year: $4.75B
-5.8%

ICU Medical

ICU Medical

ICU Medical Revenue by Segment

Forward Guidance

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company's expectations, goals or intentions regarding the future.

Revenue & Expenses

Visualization of income flow from segment revenue to net income